Navigation Links
Long-term pharmacotherapy for obesity and overweight: updated meta-analysis
Date:11/16/2007

Patients taking anti-obesity drugs will only see modest weight loss and many will remain significantly obese or overweight, according to a study published on bmj.com today.

The study, which looked at the long-term effectiveness of anti-obesity medications, found that three drugs recommended for long-term use - orlistat, sibutramine and rimonabant, reduced weight by less than 5kg (11 pounds). This equated to a loss of less than 5% of total body weight. Guidelines from the National Institute for Clinical Excellence recommend stopping the use of anti-obesity drugs if 5% of total body weight is not lost after three months.

While making changes to lifestyle and diet are recommended as the initial treatment for obesity, the use of anti-obesity drugs is common. Its estimated that in 2005 global sales of anti-obesity drugs reached $1.2billion. Current UK guidelines recommend using drug therapy in addition to making lifestyle changes if a patient has a body mass index of greater than 30.

The Canadian researchers reviewed the evidence from thirty placebo-controlled trials where adults took anti-obesity drugs for a year or longer. The mean weight of the volunteers in all of the trials was 100kg (15.7 stone). The mean body mass index levels were 35 36.

Professor Raj Padwal and colleagues found orlistat reduced weight by 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. They also found that patients taking the weight loss pills were significantly more likely to achieve 5 10% weight loss, compared to those who took the placebo.

The health benefits associated with taking the drugs varied. For example, orlistat reduced the incidence of diabetes in one trial and all three drugs lowered patients levels of certain types of cholesterol. Adverse effects were recorded with all three drugs, in particular, rimonabant increased the risk of mood disorders such as depression or anxiety. The authors noted that no trials examined rates of death and disease as a result of taking anti-obesity pills. They recommend that trials looking at this should be carried out in the future.

The authors also noted that there were high drop-out levels in all the trials. On average 30 40% of patients failed to complete the trial. They say this suggests that a failure to properly adhere to the treatment could be a major factor limiting the effectiveness of anti-obesity drug therapy.

In an accompanying editorial, Professor Gareth Williams warns of the potential damage to society if anti-obesity drugs are licensed to be sold without prescription. This already happens in the United States, and as Glaxo Smith Kline (GSK) has applied to sell orlistat over the counter throughout Europe, it could happen here. He warns:

Selling anti-obesity drugs over the counter will perpetuate the myth that obesity can be fixed simply by popping a pill and could further undermine the efforts to promote healthy living, which is the only long term escape from obesity.


'/>"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Long-Term Fatigue Plagues Cancer Survivors
3. Dont Ignore Tough or Long-Term Stomach Pain
4. Shaking may cause brain damage and serious long-term effects to infants
5. Sexual function affected by stem cell transplant according to long-term study
6. Smoking can harm the long-term effects of some oral surgery procedures
7. Childhood Obesity Epidemic a Long-Term Challenge
8. Conseco to Host Follow-Up Long-Term Care Conference Call
9. New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care
10. No Link Between Amateur Boxing, Long-Term Brain Damage
11. No strong evidence linking amateur boxing with long-term brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... be speaking on how healthcare companies can use newly released government data on ... of a population and intervene and capture the value they create to succeed ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart ... employers and organizations with the tools and information to lower the costs, and ... cut the cost of providing employee healthcare benefits by as much as 22%:, ...
(Date:2/6/2016)... ... , ... US Sports Camps is proud to sponsor the Bay Area Disc ... non-profit leaders, ultimate organizations, and coaches from around the US. The theme for this ... Director of Youth and Education, describes this year YUCC as “an important conversation we ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... new report published by Allied Market Research titled, ... Opportunities and Forecasts, 2014-2020", estimates the world synthetic ... Nucleotide synthesis and sequencing technology segment would continue ... and software tools segment, collectively, held around half ...
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  Despite ... has been slower than other industries to embrace Big ... come with utilization. On the medical side, organizations have ... improve everything from clinical trials to adherence. ... research from benchmarking firm Best Practices, LLC, Big Data ...
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical ... aesthetic device company, announced today that William ... North America, is scheduled to participate in the ... Conference on February 11, 2016 in ... allow institutional investors to meet with the Mr. ...
Breaking Medicine Technology: